arrow
B

Brian Groff

University of San Diego
H指数:9
被引数:437

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

同种免疫防御受体与粘附配体CD58的遗传剔除相结合是一种促进异基因细胞疗法功能持久性的综合方法,无需条件性化疗。

BLOOD
IF23.1
2024-11-050
PRE
High-avidity BCMA CAR and high- affinity, non-cleavable CD16 Fc receptor incorporated in off-the-shelf CAR T cells promote multi-antigen targeting and durable anti-tumor cytotoxicity in the treatment of multiple myeloma
2024-03-220
PRE
A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors
MED
IF11.8
2023-07-0110
OA
Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma
2022-11-2938
OAAI
NOVEL IMMUNE RECONSTITUTION MODEL HIGHLIGHTS THE IMPORTANCE OF STEALTH STRATEGIES THAT POTENTIATE EFFECTOR CELL FUNCTION AND PROMOTE FUNCTIONAL PERSISTENCE OF NEXT-GENERATION ADOPTIVE CELL THERAPIES
2022-11-070
OA
FT536 PATH TO IND: UBIQUITOUS TARGETING OF SOLID TUMORS WITH AN OFF-THE-SHELF, FIRST-OF-KIND MICA/B-SPECIFIC CAR-INK CELLULAR IMMUNOTHERAPY
2021-11-103
OA
Combinational strategy targeting B cell malignancy using iPSC engineered CAR-NK (FT596) and CAR-T cell (FT819) platforms with therapeutic antibody to achieve an effective deep and durable response

使用iPSC工程car-nk (FT596) 和car-t细胞 (FT819) 平台与治疗性抗体靶向b细胞恶性肿瘤的组合策略,以实现有效的深度和持久的反应

2020-08-151
PRE
Preclinical development of first-of-kind dual-targeted off-the-shelf CAR-NK cell product with engineered persistence for an effective treatment of B cell malignancies

具有工程持久性的首例双靶向现成car-nk细胞产品的临床前开发,可有效治疗b细胞恶性肿瘤

2019-07-012
PRE
FT516, an off-the-shelf engineered NK cell therapeutic product for universal anti-tumor targeting strategy in combination with monoclonal antibodies

FT516,一种现成的工程NK细胞治疗产品,用于与单克隆抗体结合的通用抗肿瘤靶向策略

2019-07-012
PRE
Renewable and genetically engineered natural killer cells for off-the-shelf adoptive cellular immunotherapy
2017-07-010
PRE